Towards Clinical Implementation of Adeno-Associated Virus (AAV) Vectors for Cancer Gene Therapy: Current Status and Future Perspectives

Towards Clinical Implementation of Adeno-Associated Virus (AAV) Vectors for Cancer Gene Therapy: Current Status and Future Perspectives

Adeno-associated virus (AAV) vectors have gained tremendous attention as in vivo delivery systems in gene therapy for inherited monogenetic diseases. First market approvals, excellent safety data, availability of large-scale production protocols, and the possibility to tailor the vector towards opti...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Cancers 2020-07, Vol.12 (7), p.1889
Hauptverfasser: Hacker, Ulrich T, Bentler, Martin, Kaniowska, Dorota, Morgan, Michael, Büning, Hildegard
Format: Artikel
Sprache:eng
Schlagworte:
Cancer
Clinical trials
Disease
Expression vectors
Gene therapy
Genetic engineering
Genomes
Hemophilia
Heparan sulfate
Immunotherapy
Liver
Medical research
Metastasis
Proteins
Review
Tumors
Vectors (Biology)
Viruses
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page
container_issue 7
container_start_page 1889
container_title Cancers
container_volume 12
creator Hacker, Ulrich T
Bentler, Martin
Kaniowska, Dorota
Morgan, Michael
Büning, Hildegard
description Adeno-associated virus (AAV) vectors have gained tremendous attention as in vivo delivery systems in gene therapy for inherited monogenetic diseases. First market approvals, excellent safety data, availability of large-scale production protocols, and the possibility to tailor the vector towards optimized and cell-type specific gene transfer offers to move from (ultra) rare to common diseases. Cancer, a major health burden for which novel therapeutic options are urgently needed, represents such a target. We here provide an up-to-date overview of the strategies which are currently developed for the use of AAV vectors in cancer gene therapy and discuss the perspectives for the future translation of these pre-clinical approaches into the clinic.
doi_str_mv 10.3390/cancers12071889
format Article
fullrecord <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_7409174</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2425002525</sourcerecordid><originalsourceid>FETCH-LOGICAL-c421t-c8b341fc07b62bcd1c221d9ee202b2ebff7a019fadaadf5c28fa955740c4d3b03</originalsourceid><addsrcrecordid>eNpdkU1LHjEUhYO0qFjX3ZVAN3YxNV_z1UVhGNQKQgt9-25DJrmpkZlkmsxY_AX-7eatVqzZ5MI95-FcDkJvKfnIeUtOtfIaYqKM1LRp2j10mCdWVFUrXj2bD9BxSjckP85pXdX76ICzqhasEofofhN-q2gS7kfnnVYjvpzmESbwi1pc8DhY3BnwoehSCtqpBQzeurgmfNJ12w94C3oJMWEbIu7_BsIX4AFvriGq-e4T7tcYMw1_z8DsUt7g83VZI-BvOfyc7e4W0hv02qoxwfHjf4R-nJ9t-i_F1deLy767KrRgdCl0M3BBrSb1ULFBG6oZo6YFYIQNDAZra0Voa5VRythSs8aqtixrQbQwfCD8CH1-4M7rMIHROVlUo5yjm1S8k0E5-f_Gu2v5M9zKjGhpLTLg5BEQw68V0iInlzSMo_IQ1iSZYCUhrGRllr5_Ib0Ja_T5vJ1KNFnFd4lOH1Q6hpQi2KcwlMhdz_JFz9nx7vkNT_p_rfI_yVenhg</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2424802530</pqid></control><display><type>article</type><title>Towards Clinical Implementation of Adeno-Associated Virus (AAV) Vectors for Cancer Gene Therapy: Current Status and Future Perspectives</title><source>MDPI - Multidisciplinary Digital Publishing Institute</source><source>EZB-FREE-00999 freely available EZB journals</source><source>PubMed Central</source><source>PubMed Central Open Access</source><creator>Hacker, Ulrich T ; Bentler, Martin ; Kaniowska, Dorota ; Morgan, Michael ; Büning, Hildegard</creator><creatorcontrib>Hacker, Ulrich T ; Bentler, Martin ; Kaniowska, Dorota ; Morgan, Michael ; Büning, Hildegard</creatorcontrib><description>Adeno-associated virus (AAV) vectors have gained tremendous attention as in vivo delivery systems in gene therapy for inherited monogenetic diseases. First market approvals, excellent safety data, availability of large-scale production protocols, and the possibility to tailor the vector towards optimized and cell-type specific gene transfer offers to move from (ultra) rare to common diseases. Cancer, a major health burden for which novel therapeutic options are urgently needed, represents such a target. We here provide an up-to-date overview of the strategies which are currently developed for the use of AAV vectors in cancer gene therapy and discuss the perspectives for the future translation of these pre-clinical approaches into the clinic.</description><identifier>ISSN: 2072-6694</identifier><identifier>EISSN: 2072-6694</identifier><identifier>DOI: 10.3390/cancers12071889</identifier><identifier>PMID: 32674264</identifier><language>eng</language><publisher>Switzerland: MDPI AG</publisher><subject>Cancer ; Clinical trials ; Disease ; Expression vectors ; Gene therapy ; Genetic engineering ; Genomes ; Hemophilia ; Heparan sulfate ; Immunotherapy ; Liver ; Medical research ; Metastasis ; Proteins ; Review ; Tumors ; Vectors (Biology) ; Viruses</subject><ispartof>Cancers, 2020-07, Vol.12 (7), p.1889</ispartof><rights>2020. This work is licensed under http://creativecommons.org/licenses/by/3.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.</rights><rights>2020 by the authors. 2020</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c421t-c8b341fc07b62bcd1c221d9ee202b2ebff7a019fadaadf5c28fa955740c4d3b03</citedby><cites>FETCH-LOGICAL-c421t-c8b341fc07b62bcd1c221d9ee202b2ebff7a019fadaadf5c28fa955740c4d3b03</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC7409174/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC7409174/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,314,723,776,780,881,27901,27902,53766,53768</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/32674264$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Hacker, Ulrich T</creatorcontrib><creatorcontrib>Bentler, Martin</creatorcontrib><creatorcontrib>Kaniowska, Dorota</creatorcontrib><creatorcontrib>Morgan, Michael</creatorcontrib><creatorcontrib>Büning, Hildegard</creatorcontrib><title>Towards Clinical Implementation of Adeno-Associated Virus (AAV) Vectors for Cancer Gene Therapy: Current Status and Future Perspectives</title><title>Cancers</title><addtitle>Cancers (Basel)</addtitle><description>Adeno-associated virus (AAV) vectors have gained tremendous attention as in vivo delivery systems in gene therapy for inherited monogenetic diseases. First market approvals, excellent safety data, availability of large-scale production protocols, and the possibility to tailor the vector towards optimized and cell-type specific gene transfer offers to move from (ultra) rare to common diseases. Cancer, a major health burden for which novel therapeutic options are urgently needed, represents such a target. We here provide an up-to-date overview of the strategies which are currently developed for the use of AAV vectors in cancer gene therapy and discuss the perspectives for the future translation of these pre-clinical approaches into the clinic.</description><subject>Cancer</subject><subject>Clinical trials</subject><subject>Disease</subject><subject>Expression vectors</subject><subject>Gene therapy</subject><subject>Genetic engineering</subject><subject>Genomes</subject><subject>Hemophilia</subject><subject>Heparan sulfate</subject><subject>Immunotherapy</subject><subject>Liver</subject><subject>Medical research</subject><subject>Metastasis</subject><subject>Proteins</subject><subject>Review</subject><subject>Tumors</subject><subject>Vectors (Biology)</subject><subject>Viruses</subject><issn>2072-6694</issn><issn>2072-6694</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2020</creationdate><recordtype>article</recordtype><sourceid>8G5</sourceid><sourceid>BENPR</sourceid><sourceid>GUQSH</sourceid><sourceid>M2O</sourceid><recordid>eNpdkU1LHjEUhYO0qFjX3ZVAN3YxNV_z1UVhGNQKQgt9-25DJrmpkZlkmsxY_AX-7eatVqzZ5MI95-FcDkJvKfnIeUtOtfIaYqKM1LRp2j10mCdWVFUrXj2bD9BxSjckP85pXdX76ICzqhasEofofhN-q2gS7kfnnVYjvpzmESbwi1pc8DhY3BnwoehSCtqpBQzeurgmfNJ12w94C3oJMWEbIu7_BsIX4AFvriGq-e4T7tcYMw1_z8DsUt7g83VZI-BvOfyc7e4W0hv02qoxwfHjf4R-nJ9t-i_F1deLy767KrRgdCl0M3BBrSb1ULFBG6oZo6YFYIQNDAZra0Voa5VRythSs8aqtixrQbQwfCD8CH1-4M7rMIHROVlUo5yjm1S8k0E5-f_Gu2v5M9zKjGhpLTLg5BEQw68V0iInlzSMo_IQ1iSZYCUhrGRllr5_Ib0Ja_T5vJ1KNFnFd4lOH1Q6hpQi2KcwlMhdz_JFz9nx7vkNT_p_rfI_yVenhg</recordid><startdate>20200714</startdate><enddate>20200714</enddate><creator>Hacker, Ulrich T</creator><creator>Bentler, Martin</creator><creator>Kaniowska, Dorota</creator><creator>Morgan, Michael</creator><creator>Büning, Hildegard</creator><general>MDPI AG</general><general>MDPI</general><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7T5</scope><scope>7TO</scope><scope>7XB</scope><scope>8FE</scope><scope>8FH</scope><scope>8FK</scope><scope>8G5</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BENPR</scope><scope>BHPHI</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>GNUQQ</scope><scope>GUQSH</scope><scope>H94</scope><scope>HCIFZ</scope><scope>LK8</scope><scope>M2O</scope><scope>M7P</scope><scope>MBDVC</scope><scope>PIMPY</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>Q9U</scope><scope>7X8</scope><scope>5PM</scope></search><sort><creationdate>20200714</creationdate><title>Towards Clinical Implementation of Adeno-Associated Virus (AAV) Vectors for Cancer Gene Therapy: Current Status and Future Perspectives</title><author>Hacker, Ulrich T ; Bentler, Martin ; Kaniowska, Dorota ; Morgan, Michael ; Büning, Hildegard</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c421t-c8b341fc07b62bcd1c221d9ee202b2ebff7a019fadaadf5c28fa955740c4d3b03</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2020</creationdate><topic>Cancer</topic><topic>Clinical trials</topic><topic>Disease</topic><topic>Expression vectors</topic><topic>Gene therapy</topic><topic>Genetic engineering</topic><topic>Genomes</topic><topic>Hemophilia</topic><topic>Heparan sulfate</topic><topic>Immunotherapy</topic><topic>Liver</topic><topic>Medical research</topic><topic>Metastasis</topic><topic>Proteins</topic><topic>Review</topic><topic>Tumors</topic><topic>Vectors (Biology)</topic><topic>Viruses</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Hacker, Ulrich T</creatorcontrib><creatorcontrib>Bentler, Martin</creatorcontrib><creatorcontrib>Kaniowska, Dorota</creatorcontrib><creatorcontrib>Morgan, Michael</creatorcontrib><creatorcontrib>Büning, Hildegard</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Immunology Abstracts</collection><collection>Oncogenes and Growth Factors Abstracts</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>Research Library (Alumni Edition)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>ProQuest Central</collection><collection>Natural Science Collection</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>ProQuest Central Student</collection><collection>Research Library Prep</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>SciTech Premium Collection</collection><collection>ProQuest Biological Science Collection</collection><collection>Research Library</collection><collection>Biological Science Database</collection><collection>Research Library (Corporate)</collection><collection>Publicly Available Content Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>ProQuest Central Basic</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Cancers</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Hacker, Ulrich T</au><au>Bentler, Martin</au><au>Kaniowska, Dorota</au><au>Morgan, Michael</au><au>Büning, Hildegard</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Towards Clinical Implementation of Adeno-Associated Virus (AAV) Vectors for Cancer Gene Therapy: Current Status and Future Perspectives</atitle><jtitle>Cancers</jtitle><addtitle>Cancers (Basel)</addtitle><date>2020-07-14</date><risdate>2020</risdate><volume>12</volume><issue>7</issue><spage>1889</spage><pages>1889-</pages><issn>2072-6694</issn><eissn>2072-6694</eissn><abstract>Adeno-associated virus (AAV) vectors have gained tremendous attention as in vivo delivery systems in gene therapy for inherited monogenetic diseases. First market approvals, excellent safety data, availability of large-scale production protocols, and the possibility to tailor the vector towards optimized and cell-type specific gene transfer offers to move from (ultra) rare to common diseases. Cancer, a major health burden for which novel therapeutic options are urgently needed, represents such a target. We here provide an up-to-date overview of the strategies which are currently developed for the use of AAV vectors in cancer gene therapy and discuss the perspectives for the future translation of these pre-clinical approaches into the clinic.</abstract><cop>Switzerland</cop><pub>MDPI AG</pub><pmid>32674264</pmid><doi>10.3390/cancers12071889</doi><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 2072-6694
ispartof Cancers, 2020-07, Vol.12 (7), p.1889
issn 2072-6694
2072-6694
language eng
recordid cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_7409174
source MDPI - Multidisciplinary Digital Publishing Institute; EZB-FREE-00999 freely available EZB journals; PubMed Central; PubMed Central Open Access
subjects Cancer
Clinical trials
Disease
Expression vectors
Gene therapy
Genetic engineering
Genomes
Hemophilia
Heparan sulfate
Immunotherapy
Liver
Medical research
Metastasis
Proteins
Review
Tumors
Vectors (Biology)
Viruses
title Towards Clinical Implementation of Adeno-Associated Virus (AAV) Vectors for Cancer Gene Therapy: Current Status and Future Perspectives
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-08T15%3A01%3A43IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Towards%20Clinical%20Implementation%20of%20Adeno-Associated%20Virus%20(AAV)%20Vectors%20for%20Cancer%20Gene%20Therapy:%20Current%20Status%20and%20Future%20Perspectives&rft.jtitle=Cancers&rft.au=Hacker,%20Ulrich%20T&rft.date=2020-07-14&rft.volume=12&rft.issue=7&rft.spage=1889&rft.pages=1889-&rft.issn=2072-6694&rft.eissn=2072-6694&rft_id=info:doi/10.3390/cancers12071889&rft_dat=%3Cproquest_pubme%3E2425002525%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2424802530&rft_id=info:pmid/32674264&rfr_iscdi=true